Portage Biotech Announces First Patient Dosed In Phase 1a Trial Of PORT-6 In Select Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Portage Biotech (NASDAQ:PRTG) has dosed the first patient in its Phase 1a trial, ADPORT-601, evaluating the adenosine 2A receptor (A2AR) antagonist candidate, PORT-6, in patients with solid tumors including prostate cancer, renal, and non-small cell lung cancer. The trial aims to evaluate the safety and efficacy of PORT-6 and plans to integrate proprietary biomarkers for patient selection.
June 26, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Portage Biotech has initiated its Phase 1a trial for PORT-6 in patients with solid tumors, which could potentially lead to advancements in cancer treatment.
The initiation of the Phase 1a trial for PORT-6 is a significant milestone for Portage Biotech, as it marks the beginning of clinical evaluation for the drug candidate. If the trial demonstrates safety and efficacy, it could lead to further development and potential advancements in cancer treatment, positively impacting the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100